A Phase 1 Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 May 2018
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 23 May 2018 Status changed from recruiting to active, no longer recruiting.
- 22 Sep 2017 Status changed from not yet recruiting to recruiting.
- 09 Aug 2017 New trial record